GlassScriptPhysician profile
Dennis Karter
NPI 1639142714
$2,751.54
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $962 · 2020: $487 · 2021: $734 · 2022: $461 · 2024: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $107.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $841.69 | 2019-2022 | |
| Viiv Healthcare Company | $742.45 | 2019-2022 | |
| Janssen Biotech, INC. | $304.98 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $253.83 | 2019-2021 | |
| Allergan, INC. | $130.09 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.36 | 2019 | |
| Hologic Sales and Service, LLC | $107.84 | 2024 | Aptima |
| Theratechnologies INC. | $106.35 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $40.09 | 2020-2021 | |
| Napo Pharmaceuticals INC | $24.26 | 2022 | |
| Bausch Health US, LLC | $24.10 | 2021 | |
| Abbvie INC. | $23.59 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $19.08 | 2019 | |
| Ibsa Pharma INC. | $15.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Karter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.